Year All2026202520242023202220212020 April 20, 2026 Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit April 9, 2026 Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles April 7, 2026 Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health April 6, 2026 Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 30, 2026 Invivyd Announces Presentation at the World Vaccine Congress Washington March 5, 2026 Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates March 5, 2026 Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer March 2, 2026 Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026 March 2, 2026 Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 24, 2026 New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies
